A Subset of PD-1-Expressing CD56 bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer.

Autor: Gascón-Ruiz M; Medical Oncology Department, University Hospital Lozano Blesa, 50009 Zaragoza, Spain.; Aragon Health Research Institute (IIS Aragón), 50009 Zaragoza, Spain., Ramírez-Labrada A; Nanotoxicology and Immunotoxicology Unit (IIS Aragón), 50009 Zaragoza, Spain.; CIBER de Enfermedades Infecciosas (CIBERINFEC), 28029 Madrid, Spain., Lastra R; Medical Oncology Department, University Hospital Lozano Blesa, 50009 Zaragoza, Spain.; Aragon Health Research Institute (IIS Aragón), 50009 Zaragoza, Spain., Martínez-Lostao L; Aragon Health Research Institute (IIS Aragón), 50009 Zaragoza, Spain.; Immunology Department, University Hospital Lozano Blesa, 50009 Zaragoza, Spain.; Department of Microbiology, Pediatrics, Radiology and Public Health, University of Zaragoza, 50009 Zaragoza, Spain.; Aragon Nanoscience Institute, 50018 Zaragoza, Spain.; Aragon Materials Science Institute, 50009 Zaragoza, Spain., Paño-Pardo JR; Aragon Health Research Institute (IIS Aragón), 50009 Zaragoza, Spain.; CIBER de Enfermedades Infecciosas (CIBERINFEC), 28029 Madrid, Spain.; Infectious Disease Department, University Hospital Lozano Blesa, 50009 Zaragoza, Spain., Sesma A; Medical Oncology Department, University Hospital Lozano Blesa, 50009 Zaragoza, Spain.; Aragon Health Research Institute (IIS Aragón), 50009 Zaragoza, Spain., Zapata-García M; Medical Oncology Department, University Hospital Lozano Blesa, 50009 Zaragoza, Spain.; Aragon Health Research Institute (IIS Aragón), 50009 Zaragoza, Spain., Moratiel A; Medical Oncology Department, University Hospital Lozano Blesa, 50009 Zaragoza, Spain.; Aragon Health Research Institute (IIS Aragón), 50009 Zaragoza, Spain., Quílez E; Medical Oncology Department, University Hospital Lozano Blesa, 50009 Zaragoza, Spain.; Aragon Health Research Institute (IIS Aragón), 50009 Zaragoza, Spain., Torres-Ramón I; Medical Oncology Department, University Hospital Lozano Blesa, 50009 Zaragoza, Spain.; Aragon Health Research Institute (IIS Aragón), 50009 Zaragoza, Spain., Yubero A; Medical Oncology Department, University Hospital Lozano Blesa, 50009 Zaragoza, Spain.; Aragon Health Research Institute (IIS Aragón), 50009 Zaragoza, Spain., Domingo MP; Instituto de Carboquímica (ICB-CSIC), Miguel Luesma 4, 50018 Zaragoza, Spain., Esteban P; Aragon Health Research Institute (IIS Aragón), 50009 Zaragoza, Spain., Gálvez EM; CIBER de Enfermedades Infecciosas (CIBERINFEC), 28029 Madrid, Spain.; Instituto de Carboquímica (ICB-CSIC), Miguel Luesma 4, 50018 Zaragoza, Spain., Pardo J; Aragon Health Research Institute (IIS Aragón), 50009 Zaragoza, Spain.; CIBER de Enfermedades Infecciosas (CIBERINFEC), 28029 Madrid, Spain.; Microbiology, Radiology, Pediatry and Public Health Department Medicine, University of Zaragoza, 50009 Zaragoza, Spain., Isla D; Medical Oncology Department, University Hospital Lozano Blesa, 50009 Zaragoza, Spain.; Aragon Health Research Institute (IIS Aragón), 50009 Zaragoza, Spain.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2023 Jan 04; Vol. 15 (2). Date of Electronic Publication: 2023 Jan 04.
DOI: 10.3390/cancers15020329
Abstrakt: (1) Despite the effectiveness of immune checkpoint inhibitors (ICIs) in lung cancer, there is a lack of knowledge about predictive biomarkers. The objective of our study is to analyze different subsets of T-lymphocytes and natural killer (NK) cells as predictive biomarkers in a cohort of patients with nonsmall cell lung cancer (NSCLC) treated with ICI. (2) This is an observational, prospective study with 55 NSCLC patients treated with ICI. A total of 43 T and NK cell subsets are analyzed in peripheral blood, including the main markers of exhaustion, differentiation, memory, activation, and inhibition. (3) Regarding the descriptive data, Granzyme B+CD4+ Treg lymphocytes stand out (median 17.4%), and within the NK populations, most patients presented cytotoxic NK cells (CD56+CD3-CD16+GranzymeB+; median 94.8%), and about half of them have highly differentiated adaptive-like NK cells (CD56+CD3-CD16+CD57+ (mean 59.8%). A statistically significant difference was observed between the expression of PD1 within the CD56 bright NK cell subpopulation (CD56+CD3-CD16-PD-1+) ( p = 0.047) and a better OS. (4) Circulating immune cell subpopulations are promising prognostic biomarkers for ICI. Pending on validation with a larger sample, here we provide an analysis of the major circulating T and NK cell subsets involved in cancer immunity, with promising results despite a small sample size.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje